Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multiple-dose topical PF-07038124 in healthy Japanese participants
jRCT2031210127Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07038124 in atopic dermatitis (AD) and psoriasis (4 arms), sponsored by Pfizer. Primary endpoints: Number of participants with treatment-emergent adverse events (AEs) and serious adverse events (SAEs), Number of participants with clinically significant changes from baseline in vital signs and 3 more. Started Jun 2021; status: completed.
02
Drugs
PF-07038124
03
Conditions
atopic dermatitis (AD)psoriasis
Beyond the preview
Go deeper on jRCT2031210127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210127.